Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LYS006 in mild to moderate ulcerative colitis
2019-003113-34Phase 2Terminated
- Sponsor
- Novartis
- Start
- Nov 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in autoimmune colitis comparing LYS006 with Placebo (2 arms). Primary endpoint: Clinical remission rate. Started Nov 2019; status: terminated.
02
Drugs
LYS006
03
Conditions
autoimmune colitis
Beyond the preview
Go deeper on 2019-003113-34.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-003113-34.